Juniper Pharma (JNP) Announces Pipeline Candidates at Analyst Day; Roth Capital Reiterates Buy
Tweet Send to a Friend
Roth Capital reiterated a Buy rating on Juniper Pharmaceuticals (NASDAQ: JNP), and raised the price target to $20.00 (from $15.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
